Nanobiotix Shares Drop Nearly 2%, Among the Largest Declines in the SBF 120
The French biotech continues another session in the red as the Parisian market also declines. The movement is a continuation of a significant pullback that began after the historic high recorded in mid-May. However, the annual performance remains exceptional.
A Measured Decline that Extends the Digestion of the Annual Rally
Nanobiotix shares are down 1.87% at €30.38 during the session, with the SBF 120 down by 0.45%. The stock ranks at the lower end of the broad Parisian index.
The consolidation phase that began after the mid-May peak continues, even as the twelve-month performance exceeds 631%.
The biotech sector context in Paris remains mixed, with a decline in Sanofi (-0.95%) and Eurofins Scientific (-0.49%), while the CAC 40 is down 0.48%.
Below the 20-Day Moving Average, but Well Above the 200-Day Average
In terms of technical benchmarks, the price is 17.42% below its 20-day moving average (€36.79) and 3.95% below its 50-day moving average (€31.63), indicating a short-term loss of momentum. The RSI at 43 remains in a neutral zone, with no significant signs of selling exhaustion.
The magnitude of the annual rally remains evident: the stock maintains a gap of more than 40% above its 200-day moving average (€21.61). The identified support at €26.52 remains distant from the current price.
On the fundamentals, the early June published preliminary Phase 2 results of JNJ-1900 (NBTXR3), combined with a strengthened net cash position of €42.1 million as of March 31, have provided a recent factual basis. The next technical milestone to watch remains the 50-day moving average, which the price has approached.
